| Symbol | FTRE |
|---|---|
| Name | FORTREA HOLDINGS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 8 MOORE DRIVE, DURHAM, North Carolina, 22709, United States |
| Telephone | 877-495-0816 |
| Fax | — |
| — | |
| Website | https://www.fortrea.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001965040 |
| Description | Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina. Additional info from NASDAQ: |
2026-05-05 10:12
(10% Negative) FORTREA HOLDINGS INC. (FTRE) Reports Q2 2026 Financial Results
Read more
2026-04-29 19:39
New Form SCHEDULE 13G - Fortrea Holdings Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0002100119-26-000497 <b>Size:</b> 7 KB
Read more
2026-04-27 07:15
New Form ARS - Fortrea Holdings Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-178741 <b>Size:</b> 948 KB
Read more
2026-04-27 07:13
New Form DEFA14A - Fortrea Holdings Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-178735 <b>Size:</b> 820 KB
Read more
2026-04-27 07:11
New Form DEF 14A - Fortrea Holdings Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-178733 <b>Size:</b> 4 MB
Read more
2026-04-21 12:45
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
Read more
2026-04-08 02:28
Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/… | Phase2 | Colorectal Cancer | Recruiting | 2026-05-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Partic… | Phase1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | 2025-11-12 | 2028-07-03 | ClinicalTrials.gov |
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally… | Phase1 | Colorectal Cancer (Diagnosis) | Recruiting | 2025-11-01 | 2028-07-01 | ClinicalTrials.gov |
| NCT07017933 | Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surger… | Na | Renal Impairment After Cardiac Surgery | Recruiting | 2025-07-16 | 2027-06-14 | ClinicalTrials.gov |
| NCT07093398 | A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Hea… | Phase1 | Healthy Adult Volunteers | Completed | 2025-07-11 | 2025-11-17 | ClinicalTrials.gov |
| NCT06933472 | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphos… | Phase3 | Hyperphosphatemia | Recruiting | 2025-06-13 | 2027-01-10 | ClinicalTrials.gov |
| NCT06916806 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodyna… | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2025-05-01 | 2027-09-15 | ClinicalTrials.gov |
| NCT06713369 | AZD5305 hADME in Patients With Advanced Solid Malignancies | Phase1 | Locally Advanced or Metastatic Solid Tumor | Recruiting | 2025-04-02 | 2026-10-02 | ClinicalTrials.gov |
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients Wit… | Phase4 | Chronic Lymphocytic Leukaemia | Recruiting | 2025-02-04 | 2030-08-16 | ClinicalTrials.gov |
| NCT06769633 | Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 … | Phase2 | Duchenne Muscular Dystrophy | Recruiting | 2025-01-02 | 2029-12-01 | ClinicalTrials.gov |
| NCT06813781 | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, … | Phase1 | Hepatic Impairment | Completed | 2024-12-19 | 2025-10-02 | ClinicalTrials.gov |
| NCT06706817 | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic R… | Phase3 | Chronic Rhinosinusitis With Nasal Polyps | Recruiting | 2024-12-03 | 2027-01-13 | ClinicalTrials.gov |
| NCT06692764 | A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | Phase2 | Atherosclerotic Cardiovascular Disease | Completed | 2024-10-30 | 2025-05-02 | ClinicalTrials.gov |
| NCT06473779 | Open-label Study to Assess Reduction of Background Asthma Medication While Sust… | Phase3 | Severe Asthma | Active_Not_Recruiting | 2024-09-30 | 2027-06-25 | ClinicalTrials.gov |
| NCT06563102 | Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Thera… | Phase4 | Mild Asthma | Completed | 2024-09-11 | 2026-02-24 | ClinicalTrials.gov |
| NCT06398730 | A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Sa… | Phase1 | Healthy Volunteers | Completed | 2024-07-02 | 2026-02-23 | ClinicalTrials.gov |
| NCT06432647 | A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-11… | Phase1 | Healthy Volunteers | Completed | 2024-04-24 | 2024-11-25 | ClinicalTrials.gov |
| NCT05933057 | Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With D… | Phase3 | Duchenne Muscular Dystrophy | Recruiting | 2024-02-19 | 2028-02-01 | ClinicalTrials.gov |
| NCT06083012 | Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an A… | — | Atrial Fibrillation | Active_Not_Recruiting | 2023-10-27 | 2027-04-27 | ClinicalTrials.gov |
| NCT05693129 | Pediatric Patients Aged 1 to 6 Years With APDS | Phase3 | APDS | Active_Not_Recruiting | 2023-08-30 | 2026-10-28 | ClinicalTrials.gov |
| NCT05981495 | Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection K… | — | Tuberculosis, Pulmonary | Unknown | 2023-08-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05636852 | Altropane Dose for Imaging Patients With Suspected Parkinson's Disease | Phase2 | Parkinson Disease | Terminated | 2023-04-24 | 2024-06-08 | ClinicalTrials.gov |
| NCT05438407 | Pediatric Patients Aged 4 to 11 Years With APDS | Phase3 | APDS | Active_Not_Recruiting | 2023-02-01 | 2026-12-30 | ClinicalTrials.gov |
| NCT04817670 | Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With S… | Phase2 | Sickle Cell Disease | Completed | 2021-11-18 | 2024-03-07 | ClinicalTrials.gov |
| NCT04702451 | Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation | Na | Atrial Fibrillation | Completed | 2021-02-12 | 2023-12-27 | ClinicalTrials.gov |
| NCT04498026 | Adherus™ Dural Sealant in Spinal Procedures | Na | Spinal Duraplasty | Enrolling_By_Invitation | 2020-11-19 | 2025-12-01 | ClinicalTrials.gov |
Total clinical trials: 26
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07219238 |
| PVI | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| VX1 | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| Dispersion ablation + PVI | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04702451 |
| NanoDetect-TB | Other | Preclinical | Tuberculosis, Pulmonary | UNKNOWN | NCT05981495 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| ATH-1105 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| Placebo TID | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| Placebo BID | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 240 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 360 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| VIT-2763 120 mg | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT04817670 |
| DuraSeal Exact Dural Sealant System | Other | Approved | Spinal Duraplasty | ENROLLING_BY_INVITATION | NCT04498026 |
| Adherus Dural Sealant System | Other | Approved | Spinal Duraplasty | ENROLLING_BY_INVITATION | NCT04498026 |
| Placebo | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | RECRUITING | NCT05933057 |
| Givinostat | Other | Phase PHASE3 | Duchenne Muscular Dystrophy | RECRUITING | NCT05933057 |
| Givinostat Hydrochloride - Cohort 2 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT06769633 |
| Givinostat Hydrochloride | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT06769633 |
| Altropane (123I) Injection | Other | Phase PHASE2 | Parkinson Disease | TERMINATED | NCT05636852 |
| AZD5004 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| AZD5004 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07219238 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05693129 |
| Leniolisib | Other | Phase PHASE3 | APDS | ACTIVE_NOT_RECRUITING | NCT05438407 |
| Bevacizumab (Avastin) | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| Tislelizumab | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| ABT-301 | Other | Phase PHASE1 | Colorectal Cancer (Diagnosis) | RECRUITING | NCT07244705 |
| Cardiac mapping | Other | Preclinical | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06083012 |
| AP301 Low Dose | Other | Phase PHASE3 | Hyperphosphatemia | RECRUITING | NCT06933472 |
| AP301 | Other | Phase PHASE3 | Hyperphosphatemia | RECRUITING | NCT06933472 |
| AZD0780 | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT06692764 |
| Placebo | Other | Phase PHASE2 | Atherosclerotic Cardiovascular Disease | COMPLETED | NCT06692764 |
| Albuterol | Other | Phase PHASE4 | Mild Asthma | COMPLETED | NCT06563102 |
| Albuterol/Budesonide | Other | Phase PHASE4 | Mild Asthma | COMPLETED | NCT06563102 |
| [14C]-AZD5305 (therapeutic dose) | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| [14C]-AZD5305 microtracer | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| Saruparib (AZD5305) | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumor | RECRUITING | NCT06713369 |
| Static - PET/CT scan | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06398730 |
| GEH200520 Injection and GEH200521 (18F) Injection | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06398730 |
| Salbutamol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Mannitol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Albuterol/budesonide (AIRSUPRA®) | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Budesonide/formoterol | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Tezepelumab | Other | Phase PHASE3 | Severe Asthma | ACTIVE_NOT_RECRUITING | NCT06473779 |
| Renal assist device | Device | Approved | Renal Impairment After Cardiac Surgery | RECRUITING | NCT07017933 |
| D3S-001 | Other | Phase PHASE1 | Healthy Adult Volunteers | COMPLETED | NCT07093398 |
| AZD4512 monotherapy | Drug | Phase PHASE1 | B-cell Acute Lymphoblastic Leukemia (B-ALL) | RECRUITING | NCT07109219 |
| Investigator's choice of treatment | Drug | Phase PHASE4 | Chronic Lymphocytic Leukaemia | RECRUITING | NCT06651970 |
| Acalabrutinib | Other | Phase PHASE4 | Chronic Lymphocytic Leukaemia | RECRUITING | NCT06651970 |
| Tezepelumab | Other | Phase PHASE3 | Chronic Rhinosinusitis With Nasal Polyps | RECRUITING | NCT06706817 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5492 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT06916806 |
| AZD5004 | DRUG | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT06813781 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
| ATH-1105 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06432647 |
Total products: 85